{"entity":{"id":"myprostatescore-2","kind":"drug","name":"MyProstateScore 2.0","aka":["MPS2","MyProstateScore","MPS 2.0","18-gene urine test"],"tldr":"A urine test that reads 18 prostate cancer genes to estimate the chance of a cancer worth treating, to help decide on a biopsy.","summary":"Medicare's code 0403U describes \"MRNA, GENE EXPRESSION PROFILING OF 18 GENES, FIRST-CATCH URINE\", and Palmetto MolDX article A58700 lists it for the pre-biopsy and post-biopsy settings. In its development and validation study (validation cohort 743), the area under the curve for grade group 2 or higher cancer was 0.81 for MPS2 and 0.82 for MPS2+, against 0.60 for PSA alone and 0.77 for the Prostate Health Index, with negative predictive values of 95 to 99 per cent (Tosoian 2024). The maker's site refused the request, so its current owner and claims are not recorded here.","status":"established","asOf":"2026-11-04","links":[{"label":"CMS article A58700: Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer","url":"https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58700"}],"tags":["test","rna"],"related":["exodx-prostate","selectmdx"],"cancers":["prostate"],"sections":[],"technologies":["liquid-rna-biopsy","prostate-screening-psa-mri"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-tosoian-18-gene-urine-prostate-jama-oncol-2024"],"journals":[],"dependsOn":[],"notes":[],"brand":"MPS2","modality":"Urine mRNA test (18 genes, prostate biopsy decision)","mechanism":"Expression of 18 genes in first-catch urine is combined with clinical factors into a probability of clinically significant prostate cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[{"country":"US","reimbursement":"Medicare (Palmetto MolDX billing article A58700) lists MyProstateScore 2.0 for men at increased risk of prostate cancer, before and after biopsy","source":"https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=58700","asOf":"2026-11-04"}],"regulatoryEvents":[]},"route":"/drugs/myprostatescore-2/","neighbours":{"drug":[{"id":"exodx-prostate","kind":"drug","name":"ExoDx Prostate (IntelliScore)","route":"/drugs/exodx-prostate/"},{"id":"selectmdx","kind":"drug","name":"SelectMDx","route":"/drugs/selectmdx/"}],"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"liquid-rna-biopsy","kind":"technology","name":"Liquid RNA biopsy (cell-free, vesicle and platelet RNA)","route":"/technologies/liquid-rna-biopsy/"},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/"}],"paper":[{"id":"paper-tosoian-18-gene-urine-prostate-jama-oncol-2024","kind":"paper","name":"Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer","route":"/key-papers/paper-tosoian-18-gene-urine-prostate-jama-oncol-2024/"}]}}